<DOC>
	<DOCNO>NCT01238796</DOCNO>
	<brief_summary>The purpose study evaluate effect renal function biological activity telavancin use blood sample obtain subject normal renal function , severe renal impairment , end stage renal disease .</brief_summary>
	<brief_title>A Study Evaluate Effect Renal Function Biological Activity Telavancin</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Telavancin</mesh_term>
	<criteria>Weighs least 45 kg body mass index 18 40 kg/m2 , inclusive An estimated creatinine clearance value base CockcroftGault method : &gt; 80 mL/min subject normal renal function &lt; 30 mL/min subject severe renal impairment receive hemodialysis three time week subject end stage renal impairment If female , subject least 2 year postmenopausal , surgically sterile practice effective birth control , pregnant lactate Good venous access History clinically significant acute illness ( renal disease condition related renal disease renal impairment subject , stable diabetes hypertension ) Has kidney transplant still function History unexplained syncope , cardiac arrest , unexplained cardiac arrythmia torsade de pointes , structural heart disease , prolong QT interval , family history long QT syndrome Known hypersensitivity telavancin excipients formulation , history severe allergic anaphylactic reaction History consume 7 unit alcoholic beverage per week , history alcoholism substance abuse within past 2 year Known positive human immunodeficiency virus antibody For subject normal renal function , treatment prescription nonprescription drug , include complementary alternative medicine overthe counter medication , exception oral contraceptive , hormone replacement therapy , daily aspirin , occasional use acetaminophen within past 14 day For subject renal impairment , stable dose concomitant medication least 2 week prior study start take medication would interfere evaluation televancin study Has receive experimental agent within 30 day ten halflives , whichever longer , prior study drug administration Has significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior admission</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>telavancin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Severe renal disease</keyword>
	<keyword>VIBATIVÂ®</keyword>
	<keyword>ASP9809</keyword>
</DOC>